Koval M V, Oboskalova T A
Ural state medical university, Ekaterinburg, Russia.
Vopr Kurortol Fizioter Lech Fiz Kult. 2021;98(5):40-46. doi: 10.17116/kurort20219805140.
The menopausal syndrome is associated with a combination of neuropsychic, autonomic, vascular, and metabolic disorders. Sex steroids regulate neurotransmitter metabolism, activate neuronal plasticity, improve cerebral blood flow, maintain a stable mood, and have an antidepressant effect. In Russia, only 1% of women use menopausal hormone therapy (MHT). The reason for the low adherence to MHT is avoidance of using hormones because of the possible risks of cancer.
To evaluate the effect of subnarcotic doses of xenon on the menopausal syndrome signs in patients during the menopausal transition.
A comparative study including 32 randomly selected female patients with menopausal syndrome during the menopausal transition was conducted. Group 1 (the study treatment group) included 16 patients who refused to use MHT. They received a course of xenon therapy, consisting of 5 procedures every other day. Group 2 (control group) included 16 patients receiving MHT. Menopausal symptoms were assessed using the Greene Menopausal Scale. Psychoemotional status was determined using the Spielberger-Hanin neuropsychological test. Estradiol and progesterone concentrations were measured in a morning saliva sample to determine the steroid profile. The parameters were assessed and compared at baseline and 1 month after the start of therapy.
In assessing the severity of the menopausal syndrome in women in both groups, the significantly decreased mean final Green's scale score was observed: from 17.12±3.28 to 6.12±4.34 points in group 1 and from 16.01±4.12 to 4.02±3.12 points in group 2. Also a significant decrease in state and trait anxiety compared with baseline data was demonstrated. In the study treatment group, the trait anxiety score decreased from 53.1 [35.1; 66.0] to 27.2 [25.3; 30.0] points, and in the control group, from 55.6 [38.2; 70.4] to 22.0 [20.2; 25.0] points. Similar change was shown for the state anxiety score in the study groups. A decrease from 40.1 [35.3; 45.0] to 21.0 [23.2; 27.3] points in group 1 and from 46.1 [45.2; 52.0] to 20.1 [16.3; 23.0] points in group 2 was observed. At one month, the significant increase of estradiol (from 1.1 [0.5; 2.1] to 12.2 [10.3; 14.4] pg/mL) and progesterone (from 14.0 [4.4; 20.1] to 100.2 [60.6; 130.0] pg/mL) was observed in the MHT group of patients. No significant changes in hormone levels were recorded in the xenon therapy group.
The xenon inhalations in subnarcotic doses are an effective method to control the vasomotor and psychoemotional signs and symptoms of the menopausal syndrome in patients who refuse to use MHT or have contraindications to this type of therapy.
更年期综合征与神经精神、自主神经、血管和代谢紊乱的综合症状相关。性类固醇调节神经递质代谢，激活神经元可塑性，改善脑血流量，维持稳定情绪，并具有抗抑郁作用。在俄罗斯，只有1%的女性使用更年期激素疗法（MHT）。MHT依从性低的原因是由于可能存在的癌症风险而避免使用激素。
评估亚麻醉剂量氙气对处于绝经过渡期患者更年期综合征症状的影响。
进行了一项比较研究，随机选取32名处于绝经过渡期的患有更年期综合征的女性患者。第1组（研究治疗组）包括16名拒绝使用MHT的患者。她们接受了一个疗程的氙气治疗，每隔一天进行5次治疗。第2组（对照组）包括16名接受MHT的患者。使用格林更年期量表评估更年期症状。使用斯皮尔伯格 - 哈宁神经心理测试确定心理情绪状态。在早晨的唾液样本中测量雌二醇和孕酮浓度以确定类固醇谱。在基线和治疗开始后1个月评估并比较这些参数。
在评估两组女性更年期综合征的严重程度时，观察到格林量表的最终平均得分显著降低：第1组从17.12±3.28分降至6.12±4.34分，第2组从16.01±4.12分降至4.02±3.12分。与基线数据相比，状态焦虑和特质焦虑也显著降低。在研究治疗组中，特质焦虑得分从53.1[35.1; 66.0]降至27.2[25.3; 30.0]分，在对照组中从55.6[38,2; 70.0]降至22.0[20.2; 25.0]分。研究组的状态焦虑得分也有类似变化。第1组从40.1[35.3; 45.0]降至21.0[23.2; 27.3]分，第2组从46.1[45.2; 52.0]降至20.1[16.3; 23.0]分。在1个月时，观察到MHT组患者的雌二醇（从1.1[0.5; 2.1]升至12.2[10.3; 14.4]pg/mL）和孕酮（从14.0[4.4; 20.1]升至100.2[60.6; 130.0]pg/mL）显著增加。氙气治疗组的激素水平未记录到显著变化。
对于拒绝使用MHT或有此类治疗禁忌症的患者，亚麻醉剂量的氙气吸入是控制更年期综合征血管舒缩和心理情绪症状的有效方法。
